Business
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019
Sun BioPharma, Inc. Provides a Business Update and Files Report for Q1 2019.
About this update from Panbela Therapeutics, Inc.
[{"type":"text","content":"\nEnrollment in Second Cohort of PDA Combination Study CompletedNew Funding Totaling $0.8 Million Secured MINNEAPOLIS, May 14, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, today provides a business update and reports financial results for the quarter ended March 31, 2019.\n Front-Line Combination PDA StudyThe Company’s current trial, a Phase 1a/1b combination of SBP-101 to be administered with gemcitabine and nab-paclitaxel in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (PDA), completed cohort 2 enrollment and expects the Data Safety Monitoring Board to meet before the end of May 2019 to review interim results of the cohort. The Company also added a fifth clinical site, the John Flynn Private Hospital in Tugun, Queensland Australia at the end of the first quarter.  In the Phase 1a portion of this study treatment of up to 18 PDA patients was planned in three cohorts to determine a recommended dose of SBP-101 to be given in combination with standard treatment.  The Phase 1b portion will be an expansion at the recommended dose of SBP-101 and will guide SBP-101’s subsequent development for patients with PDA.  This multi-center, front-line study has 3 other sites in Australia: The Austin Health Cancer Trials Centre in Melbourne, The Adelaide Cancer Centre in Adelaide, The Blacktown Cancer and Haematology Centre in Sydney and one site in the United States, The University of Florida Health Cancer Center in Gainesville, Florida. The Company intends to open additional clinical sites in the US in anticipation of the expansion phase of the study. Suzanne Gagnon, MD, Chief Medical Officer for Sun BioPharma, Inc. commented, “Currently one additional cohort is planned prior to entering the expansion phase; we have amended our protocol to include up to 36 patients in Phase 1b.  Based on our prior study we plan to follow these patients for overall survival in addition to tumor response, disease control rate and progression free survival.” Completion of Sale of Convertible Notes   During the quarter ended March 31, 2019 the Company completed the sale of convertible notes payable which was initiated in the last quarter of 2018 ...